ripekg:evaluation/RIPEA44B073B6366CEDA7 |
prov:wasInformedBy |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
rdf:type |
rdfs:Resource |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
rdf:type |
owl:Thing |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
rdf:type |
ripe:EvidenceAggregationEvidence aggregation |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
rdf:type |
tido:Activity |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
prov:startedAtTime |
2025-10-30T15:12:38.055945Z |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI 1.0.0 |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA44B073B6366CEDA7 |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
ripekg:registry-evidence/RIPEA44B073B6366CEDA7 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |